Literature DB >> 30539312

Evaluation of the adherence of distress screening with the distress thermometer in cancer patients 4 years after implementation.

Anna Götz1,2, A Kröner3, J Jenewein3, R Spirig4,5.   

Abstract

PURPOSE: Identifying and assessing psychosocial distress with an appropriate screening instrument is essential when caring for cancer patients. Since 2012, the distress thermometer (DT) has been used by nurses for all cancer inpatients at the Comprehensive Cancer Center Zurich. We wanted to identify nurses' adherence to the screening protocol, differences between screened and not screened patients and the relationship between screening rate and productivity.
METHODS: This retrospective descriptive study used screening and referral data as well as socioeconomic and disease-related data of inpatients at the Comprehensive Cancer Center Zurich. This was collected from the electronic patient documentation system. Additionally, data showing the productivity of all wards was used. All data were analyzed descriptive.
RESULTS: Since 2012, 40.6% (4541) of the 11,184 patients have been screened. The screening rate was initially significantly lower but settled at 40% after 2 years. There was a higher screening rate among Swiss, married, male, and emergency patients and patients with hematology diseases, brain tumors, or head and neck cancer (p < 0.001). Every fourth patient with a moderate to severe distress level requested referral to a psychosocial service. Significantly more screened patients were referred to the social service (44.7%) than to the psycho-oncology service (9.4%). Only 22.9% of all referrals were made on the day of screening or a day later. There were only two wards of 15 with a significant relationship between productivity and screening rate.
CONCLUSIONS: Screening is useful in recognizing distress among patients, but screening practice needs to be reconsidered.

Entities:  

Keywords:  Distress screening; Distress thermometer; Psychosocial support

Mesh:

Year:  2018        PMID: 30539312     DOI: 10.1007/s00520-018-4579-1

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  6 in total

1.  Towards identifying cancer patients at risk to miss out on psycho-oncological treatment via machine learning.

Authors:  Moritz Philipp Günther; Johannes Kirchebner; Jan Ben Schulze; Roland von Känel; Sebastian Euler
Journal:  Eur J Cancer Care (Engl)       Date:  2022-02-09       Impact factor: 2.328

2.  Advancing the science of distress screening and management in cancer care.

Authors:  Kristine A Donovan; Luigi Grassi; Teresa L Deshields; Cheyenne Corbett; Michelle B Riba
Journal:  Epidemiol Psychiatr Sci       Date:  2020-01-09       Impact factor: 6.892

3.  Stress-Related Growth Scale-Short Form: A Portuguese validation for cancer patients.

Authors:  Magda A Oliveira; Marina P Guerra; Leonor Lencastre; Sónia Castro; Susana Moutinho; Crystal L Park
Journal:  Int J Clin Health Psychol       Date:  2021-07-24

4.  Study protocol: the OptiScreen-Study: optimized psycho-oncological care-from screening to intervention.

Authors:  Tanja Zimmermann; Lara Dreismann; Viktoria Ginger; Marit Wenzel; Beate Hornemann; Franziska Dietzsch; Charis Sura; Martin Bornhäuser; Anja Mehnert-Theuerkauf; Svenja Heyne; Ines Gockel; Florian Lordick; Anke Franzke; Jürgen Weitz; Arndt Vogel
Journal:  J Cancer Res Clin Oncol       Date:  2022-09-27       Impact factor: 4.322

5.  Web-Based Patient-Reported Outcome Measures for Personalized Treatment and Care (PROMPT-Care): Multicenter Pragmatic Nonrandomized Trial.

Authors:  Afaf Girgis; Ivana Durcinoska; Anthony Arnold; Joseph Descallar; Nasreen Kaadan; Eng-Siew Koh; Andrew Miller; Weng Ng; Martin Carolan; Stephen A Della-Fiorentina; Sandra Avery; Geoff P Delaney
Journal:  J Med Internet Res       Date:  2020-10-29       Impact factor: 5.428

6.  Psychosocial and Functional Distress of Cancer Patients in A Tertiary Care Hospital: A Descriptive Cross-sectional Study.

Authors:  Guru Sharan Sah
Journal:  JNMA J Nepal Med Assoc       Date:  2019 Jul-Aug       Impact factor: 0.406

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.